Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice

Transplantation

Volumn 76, Issue 8, 2003, Pages 1166-1170

  Matsumoto, Yuji ^a   Hof, Akiko ^a   Baumlin, Yves ^a   Hof, Robert P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYCLOSPORIN A; EVEROLIMUS; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY GRAFT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CAROTID ARTERY ALLOGRAFT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MOUSE; MOUSE STRAIN; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VASCULAR DISEASE; WILD TYPE;

ANIMALS; APOLIPOPROTEINS E; BODY WEIGHT; CAROTID ARTERIES; CHOLESTEROL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYOCARDIUM; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TUNICA INTIMA;

EID: 0242268930     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000090393.75600.32     Document Type: Article

References (27)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801.
2. Häyry P, Mennander A, Yilmaz S, et al. Towards understanding the pathophysiology of chronic rejection. Clin Invest 1992; 70: 780.
3. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331.
4. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333.
5. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343.
6. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
7. Wehr S, Rudin M, Joergensen J, et al. Allo- and autotransplantation of carotid artery: A new model of chronic graft vessel disease. Evaluation by magnetic resonance imaging and histology. Transplantation 1997; 64: 20.
8. Nikolova Z, Hof A, Baumlin Y, et al. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD. Transpl Immunol 2000; 8: 115.
9. Nikolova Z, Hof A, Baumlin Y, et al. Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model. Transplantation 2001; 72: 168.
10. Nikolova Z, Hof A, Baumlin Y, et al. Efficacy of SDZ RAD compared with CsA monotherapy and combined RAD/FTY720 treatment in a murine cardiac allotransplantation model. Transpl Immunol 2001; 9: 43.
11. Nikolova Z, Hof A, Rudin M, et al. Prevention of graft vessel disease by combined FTY720/cyclosporine: A treatment in a rat carotid artery transplantation model. Transplantation 2000; 69: 2525.
12. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
13. Adams DH, Tilney NL, Collins JJJ, et al. Experimental graft arteriosclerosis: I. The Lewis-to-F-344 allograft model. Transplantation 1992; 53: 1115.
14. Tu Y, Stepkowski SM, Chou TC, et al. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177.
15. Kroczek RA, Black CD, Barbet J, et al. Mechanism of action of cyclosporin A in vivo: I. Cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens. J Immunol 1987; 139: 3597.
16. Koskinen PK, Lemström KB, Häyry PJ. How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. Am J Pathol 1995; 146: 972.
17. Nishimura T, Faul JL, Berry GJ, et al. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001; 163: 498.
18. Vildicky O, Zou H, Muller V, et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497.
19. Salminen US, Maasilta PK, Taskinen EI, et al. Obliterative lesions in a heterotopic bronchial xenograft model: A preliminary study. Transplantation 2000; 70: 48.
20. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998; 30: 2200.
21. Schuurman HJ, Pally C, Weckbecker G, et al. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999; 31: 1024.
22. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277.
23. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24: 53.
24. Kovarik JM, Kaplan B, Tedesco SH, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation 2002; 73: 920.
25. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417.
26. Takeda Y, Miyamori I, Furukawa K, et al. Mechanisms of FK 506-induced hypertension in the rat. Hypertension 1999; 33: 130.
27. Zoja C, Furci L, Ghilardi F, et al. Cyclosporin-induced endothelial cell injury. Lab Invest 1986; 55: 455